6533b81ffe1ef96bd1278c59

RESEARCH PRODUCT

Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs

Fabian SchlottDominik SteublDieter HoffmannEdouard MatevossianJens LutzUwe HeemannVolker HöselDirk H BuschLutz RendersMichael Neuenhahn

subject

Cytomegalovirus InfectionMaleViral DiseasesT-Lymphocyteslcsh:MedicineCytomegalovirusPathology and Laboratory MedicineCell-Mediated ImmunityWhite Blood CellsAnimal CellsMedicine and Health SciencesRenal TransplantationPublic and Occupational Healthlcsh:ScienceImmunity CellularT CellsCold Ischemiavirus diseasesVaccination and ImmunizationTissue DonorsInfectious DiseasesMedical MicrobiologyViral PathogensVirusesCytomegalovirus InfectionsHuman CytomegalovirusFemaleCellular TypesPathogensResearch ArticleHerpesvirusesImmune CellsImmunologySurgical and Invasive Medical ProceduresCytotoxic T cellsSerogroupMicrobiologyUrinary System ProceduresHumansViremiaMicrobial PathogensTransplantationBlood CellsProphylaxislcsh:ROrganismsImmunityBiology and Life SciencesCell BiologyOrgan TransplantationKidney Transplantationlcsh:QPreventive MedicineDNA viruses

description

Human Cytomegalovirus (CMV) can lead to primary infection or reactivation in CMV-seronegative or -seropositive kidney transplant recipients, respectively. Complications comprise severe end-organ diseases and acute or chronic transplant rejection. Risk for CMV manifestation is stratified according to the CMV-IgG-serostatus, with donor+/recipient- (D+/R-) patients carrying the highest risk for CMV-replication. However, risk factors predisposing for primary infection in CMV-seronegative recipients are still not fully elucidated. Therefore, we monitored D+/R- high-risk patients undergoing kidney transplantation in combination with antiviral prophylaxis for the incidence of CMV-viremia for a median follow-up time of 784 days (156-1155 days). In this period, we analyzed the functional CMV-specific T cell response by intracellular cytokine staining and CMV-serology by ELISA. Only four of eight D+/R- patients developed clinically relevant CMV-viremia followed by seroconversion. Viremia triggered expansion of functional CMV-specific T cells correlating with protection against secondary CMV-reactivations. In contrast, all other patients remained permanently aviremic and showed no immunological correlate of infection after discontinuation of antiviral prophylaxis for up to three years. Comparing cold ischemic times (CIT) of viremic (median = 1020 min; 720-1080 min) and aviremic patients (median = 335 min; 120-660 min) revealed significantly (p = 0.0286) protracted CIT in patients with primary CMV-infection. Taken together, primary CMV-infection affects only a subgroup of D+/R- patients correlating with length of CIT. Therefore, patients with extended CIT should be thoroughly monitored for CMV-replication well beyond discontinuation of antiviral prophylaxis. In contrast, patients with short CIT remained permanently uninfected and might benefit from shorter prophylactic treatment.

10.1371/journal.pone.0171035http://europepmc.org/articles/PMC5271354